Alcista
$131.89
Precio del escenario
$162.990
-4.140 (-2.54%)Al cierre
ICU Medical, Inc. develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications. Its product portfolio includes ambulatory, syringe, and large volume intravenous (IV) pumps and safety software, dedicated and non-dedicated IV sets, needlefree IV connectors, peripheral IV catheters, sharps safety products, and sterile IV solutions. Its product offerings also include Consumables, Infusion Systems and Vital Care. Its consumables business unit includes infusion therapy, oncology, vascular access, and tracheostomy products. Its infusion systems offer a portfolio of infusion pumps, software, and professional services. Its vital care business unit includes hemodynamic monitoring, general anesthesia and respiratory, temperature management solutions and regional anesthesia/pain management products. Its infusion therapy products include infusion sets, extension sets, needle-free connectors, and disinfection caps.
ICU Medical Inc is a good buy right now due to its strong financial performance and positive analyst sentiment. The current price is $162.99, and the forward P/E ratio is 16.95, suggesting the stock is reasonably valued compared to its earnings potential. Additionally, the gross margin has improved significantly to 42.61% in Q2 2026, indicating strong profitability. However, the main risk is the recent insider selling, with the CFO selling shares valued at $1.1 million, which could raise concerns among investors.
Needham
$187
2026-08-07
Needham
2026-08-07
Precio objetivo
$187
Raymond James
$200
2026-08-07
Raymond James
2026-08-07
Precio objetivo
$200
BTIG
$200
2026-08-07
BTIG
2026-08-07
Precio objetivo
$200
BTIG
$170
2026-06-15
BTIG
2026-06-15
Precio objetivo
$170
Needham
$165
2026-05-27
Needham
2026-05-27
Precio objetivo
$165
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

ICU Medical CFO Sells 6,381 Shares of Stock

ICU Medical CFO Sells Shares, No Cause for Alarm

ICU Medical CFO Sells Shares, Market Reaction Stable

ICU Medical CFO Sells Shares, Market Reaction Stable

ICU Medical to Participate in Multiple Investor Conferences
ICU Medical, Inc. develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications. Its product portfolio includes ambulatory, syringe, and large volume intravenous (IV) pumps and safety software, dedicated and non-dedicated IV sets, needlefree IV connectors, peripheral IV catheters, sharps safety products, and sterile IV solutions. Its product offerings also include Consumables, Infusion Systems and Vital Care. Its consumables business unit includes infusion therapy, oncology, vascular access, and tracheostomy products. Its infusion systems offer a portfolio of infusion pumps, software, and professional services. Its vital care business unit includes hemodynamic monitoring, general anesthesia and respiratory, temperature management solutions and regional anesthesia/pain management products. Its infusion therapy products include infusion sets, extension sets, needle-free connectors, and disinfection caps. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
ICU Medical Inc is a good buy right now due to its strong financial performance and positive analyst sentiment. The current price is $162.99, and the forward P/E ratio is 16.95, suggesting the stock is reasonably valued compared to its earnings potential. Additionally, the gross margin has improved significantly to 42.61% in Q2 2026, indicating strong profitability. However, the main risk is the recent insider selling, with the CFO selling shares valued at $1.1 million, which could raise concerns among investors.
5 analysts cover ICUI: 2 rate it Buy, 3 Hold and 0 Sell. The average price target is 173.50.
Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.